X

Trial Profile

A First-in-Human Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of DS-2319 in Healthy Adults

Status: Discontinued

Phase of Trial: Phase I

Latest Information Update: 21 Jun 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Nafamostat (Primary)
Indications COVID 2019 infections
Focus Adverse reactions; First in man; Pharmacokinetics
Sponsors Daiichi Sankyo Company

Most Recent Events

15 Jun 2021 According a Daiichi Sankyo Company media release, based on situations of ongoing non-clinical studies and the phase 1 trial, the company has decided to discontinue the development of DS-2319.
15 Jun 2021 Status changed from recruiting to discontinued, according to a Daiichi Sankyo Company media release.
31 Mar 2021 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com